SCHEMBL3897995

SCHEMBL3897995

CCOc1cccc(-c2nc(C)ccc2Oc2ccnc3cc(OC)c(OC)cc23)c1

nearest known ligand 0.66

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.50
PDGFRB P09619 1/20 0.49
PDGFRA P16234 1/20 0.49
FGFR2 P21802 2/20 0.46
SRC P12931 1/20 0.44
TGFBR1 P36897 1/20 0.44
AURKA O14965 1/20 0.44
LCK P06239 1/20 0.44
MET P08581 1/20 0.44
KDR P35968 1/20 0.44
TEK Q02763 1/20 0.44
AURKB Q96GD4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3899627 0.92 EGFR (0.54) EGFRPDGFRBPDGFRAFGFR2SRC
SCHEMBL3902530 0.86 SRC (0.54) EGFRPDGFRBPDGFRAFGFR2SRC
SCHEMBL3897952 0.85 FGFR2 (0.56) EGFRPDGFRBPDGFRAFGFR2SRC
SCHEMBL3892459 0.85 PDGFRA (0.49) EGFRPDGFRBPDGFRASRCTGFBR1
SCHEMBL3904293 0.85 SRC (0.49) EGFRPDGFRBPDGFRAFGFR2SRC
SCHEMBL3906455 0.85 PDGFRB (0.49) EGFRPDGFRBPDGFRAFGFR2SRC
SCHEMBL3895661 0.85 PDGFRA (0.49) EGFRPDGFRBPDGFRAFGFR2SRC
SCHEMBL3894296 0.84 SRC (0.47) EGFRPDGFRBPDGFRASRCTGFBR1
SCHEMBL3897461 0.82 FGFR2 (0.59) EGFRPDGFRBPDGFRAFGFR2SRC
SCHEMBL3895953 0.82 PDGFRB (0.46) EGFRPDGFRBPDGFRAFGFR2SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090312313-A1 COMPOUND HAVING TGFBETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2009-12-17 US disclosed
US-20090312313-A1 COMPOUND HAVING TGFBETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2009-12-17 US disclosed
US-20090312313-A1 COMPOUND HAVING TGFBETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2009-12-17 US disclosed
US-7560558-B2 Compound having TGFβ inhibitory activity and medicinal composition containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2009-07-14 US disclosed
US-7560558-B2 Compound having TGFβ inhibitory activity and medicinal composition containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2009-07-14 US disclosed
US-7560558-B2 Compound having TGFβ inhibitory activity and medicinal composition containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2009-07-14 US disclosed
US-20060111375-A1 Compound having tgfß inhibitory activity and medicinal composition containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-05-25 US disclosed
EP-1548008-A1 COMPOUND HAVING TGF-BETA INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2005-06-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111375-A1 Compound having tgfß inhibitory activity and medicinal composition containing the same TGFB1, TGFBR1, TGFBR2 EGFR 80/4885PDGFRB 16/4885PDGFRA 36/4885
US-20090312313-A1 COMPOUND HAVING TGFBETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME TGFB1, TGFBR1, TGFBR2 EGFR 90/4885PDGFRB 14/4885PDGFRA 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.